Publications
93
Citations
285
Est. group size
—
Recurring co-author estimate
Active years
13
Publishing since 2014
Christopher D. Collier conducts research in cancer medicine, with a focus on bone and soft-tissue tumors such as osteosarcoma and sarcoma. A recent line of work uses three-dimensional tumor cell clusters (spheroids) to test already-approved cancer drugs, aiming to identify existing medicines that could be repurposed for these cancers. The work spans laboratory drug screening and translational cancer biology.
Publication activity was modest and steady from 2017 through 2024 (typically a few papers per year) before a sharp spike in 2025, largely reflecting a single multi-part study.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Current awards run through April 2030 — about 4 years of funding on record from today. Awards are often renewed, so this is what is currently public, not a forecast.
Metastatic Bone Disease and IL-6 as Drivers of Cachexia in Kidney Cancer
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~13 · 15% small-team papers (≤3 authors) · across 14 venues
- Figure 4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure S3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure S9 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Table S3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Table 1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure S8 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure S7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure 3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
Cancer Research Communications · 2025
- Table S1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure S2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- Figure S10 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
2025
- What Is the Cumulative Incidence of Femoral Stem Revision and Stem Complication in Cemented and Uncemented Hip Arthroplasty for Proximal Femoral Metastatic Bone Disease?
Clinical Orthopaedics and Related Research · 2025
- Repurposing Romidepsin for Osteosarcoma: Screening FDA-Approved Oncology Drugs with Three-Dimensional Osteosarcoma Spheroids
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- From Birth to Practice: An Analysis of Migration Patterns Among U.S. Orthopaedic Surgeons
Proceedings of IMPRS · 2025
- Clinical Orthopaedics and Related Research×7
- Proceedings of IMPRS×6
- Journal of Bone and Joint Surgery×2
- PubMed×2
- Advances in experimental medicine and biology×2
- M. Reza Saadatzadeh
Medicine · Indiana University
- Michael J. Ferguson
Medicine · Indiana University
- Karen E. Pollok
Medicine · Indiana University
- Bhuvana A. Setty
Medicine · The Ohio State University
- Elissa A. Boguslawski
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile